dimanche 15 novembre 2026
RechercherExplore
Source trace. Via News points to the documents behind its reporting and shows what we drew from each, so you can check any claim. How we source
Source document· July 10, 2026

Pepeto Passes $10.4 Million While the BNB Price Prediction Target $2,000 As Best Crypto To Buy

View original at globenewswire.com
Pepeto Passes $10.4 Million While the BNB Price Prediction Target $2,000 As Best Crypto To Buy DUBAI, United Arab Emirates, July 10, 2026 (GLOBE NEWSWIRE) -- Crypto presale Pepeto moved past $10.431 million, and traction like that in a red market raises one question…
Opening lines of the source · short snapshot: read the full document at the original

Ce que nous avons tiré de cette source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Pepeto sits first among crypto presales this year by capital raised, following the exchange token model.

    60% confidence
  • Pepeto built a zero-fee exchange running on its own token, plus a cross-chain bridge linking Ethereum, BNB Chain, and Solana with no gas cost.

    60% confidence
  • Pepeto has 420 trillion tokens priced at $0.0000001881, with 30% of supply allocated to presale tokens; a climb to a $300 million market cap would mean roughly 50x, turning $5,000 into $250,000, and matching PEPE's peak would push well past 100x.

    60% confidence
  • Early BNB buyers entered the 2017 ICO at $0.10 per token when it had barely any market value.

    60% confidence
  • BNB is trading near $577.

    60% confidence
  • The top BNB price prediction for a full bull cycle is $2,060.

    60% confidence
  • A run from $577 to $2,000 for BNB is about a 3.5x return, turning $1,000 into roughly $3,500.

    60% confidence

Data points we hold from this source

Pepeto · token price0.0000001881 USD
Pepeto · funding raised10.41 USD
Ce que nous savons · l'intelligence derrière cette page
En direct du substrat
Ce que nous observons
Q4 2026 Biotech Catalyst Cluster: Late-Stage Data and PDUFA Dates Converge
Early-to-mid November 2026 is a dense run of clinical readouts and Q3 earnings at AHA, AASLD, ACR and ASH. Mid-cap biotechs (Vir, Mineralys, Arrowhead, Oryzon, Novartis, J&J) are reporting data that feeds into regulatory decisions. The next ones are the ivonescimab BLA (Nov 14) and the lorundrostat PDUFA (Dec 22), followed by ECLIPSE 2/3 and Maritime-1 readouts in Q1 2027. The list also includes an unrelated delisting track (EGM Nov 19, application Jan 25, 2027), and the facts have no AI or fintech content.
Notre lecture des données ›
Signaux que nous suivons
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Tendances que nous surveillons ›
Là où les sources divergent
Sources réconciliées : aucun conflit ouvert pour l'instant.
Nous signalons les conflits ouvertement ›
Vérifié récemment
✓ Vérifié avec la source d'origine
4,959
faits reliés à leur source, et nous signalons ceux qui ne tiennent pas.
101 entités suivies4,959 faits vérifiés avec la source5,585 documents sources archivés
Interrogez ces données → isubstrate.com
Pepeto Passes $10.4 Million While the BNB Price Prediction Target $2,000 As Best Crypto To Buy: Source | Via News | fr.via.news